RxDoctor Payments Data

Trevor Kindle

Ophthalmology · Yankton, SDNPI 1548794316

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 56.0% of the total. Reporting peaked in 2024 at $90 and has fallen 71.3% since, to $26 in 2025. That places this record below the midpoint for ophthalmology clinicians in SD, where the typical reported total is $1,431.

$160in general payments, 2019–2025

Across 6 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$90
  • Boston Scientific$26
  • Dompe US, Inc.$17
  • Johnson & Johnson Surgical Vision, Inc.$14
  • Aerie Pharmaceuticals, Inc.$14

What the payments were for

  • Food & beverage$160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$160 in reported general payments places this provider in the 25th percentile of 52 ophthalmology providers in South Dakota.

See all ophthalmology providers in South Dakota

Medicare billing

Part B allowed, 2024
$377,012
Medicare patients
593
Services billed
3,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate450$19,058
LumiganBimatoprost21$11,159
Ofloxacin448$5,683
Cyclosporine11$5,676
VyzultaLatanoprostene Bunod14$5,556
RhopressaNetarsudil Mesylate11$4,615
CombiganBrimonidine Tartrate/Timolol22$4,228
Latanoprost203$2,097
Ketorolac Tromethamine117$1,978
Travoprost11$1,078
Timolol Maleate66$704
Dorzolamide Hcl31$687
Brimonidine Tartrate41$682
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat41$522
ErythromycinErythromycin Base14$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$90$5,55614 claims
Aerie Pharmaceuticals, Inc.Rhopressa$14$4,61511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 52 ophthalmology providers in South Dakota.

Other ophthalmology in Yankton

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →